Sanofi-Aventis has acquired Zentiva N.V.
Sanofi-Aventis has successfully completed and settled the voluntary tender offer for all of Zentiva N.V.'s shares. Total value of this transaction is over US$2 billion.
Sanofi-Aventis, a leading global pharmaceutical company, discovers, develops and distributes a broad offering of medicines, vaccines and integrated healthcare solutions adapted to local needs and means. Sanofi-Aventis is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Zentiva N.V. is an international pharmaceutical company focused on developing, manufacturing and marketing modern generic pharmaceutical products. The company has leading positions in the pharmaceutical markets in the Czech Republic, Slovakia, Romania and Turkey, and is growing rapidly in Poland, Russia, Bulgaria, Hungary, the Ukraine and the Baltic States.
Oaklins' team in the Czech Republic acted as the tender agent to Sanofi-Aventis in relation to the voluntary tender offer for all of Zentiva N.V.'s shares. From July 2008 to March 2009, the Czech team arranged the purchase of approximately 70% of the issued share capital of Zentiva.
Talk to the deal team
Related deals
Alcidion has raised capital
Alcidion Group Ltd. (ASX:ALC) has raised capital via an institutional placement. The placement was well supported by existing shareholders whilst also welcoming several new institutional shareholders to the register. Proceeds from the raise will provide Alcidion with maximum flexibility and ensure a strong balance sheet to execute on its market opportunities and enable the firm to continue to drive revenue growth.
Learn moreA group of Chilean investors has acquired Farmacias Ahumada
A group of Chilean investors has acquired Farmacias Ahumada S.A. from Walgreens Boots Alliance.
Learn moreShield Therapeutics has completed a fundraising
Shield Therapeutics plc has raised funds to bolster the expansion of ACCRUFeR®, the sole FDA-approved therapy for iron deficiency and to drive the business. Additionally, it positions the company for further investments.
Learn more